NCT00343551已完成3 期
A Nine-week, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren 300 mg Compared to Irbesartan 300 mg and Ramipril 10 mg in the Setting of a Missed Dose in Patients With Essential Hypertension
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 654
- 试验地点
- 2
- 主要终点
- from baseline.
研究概览
简要总结
The purpose of this study is to investigate the efficacy (blood pressure lowering effect) and safety of aliskiren given to hypertensive patients after a missed dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Outpatients 18 years of age and older.
- •Patients must meet following blood pressure criteria:
- •At Visit 2 : Office Mean Sitting Diastolic Blood Pressure ≥ 90 mmHg and < 110 mmHg At Visit 3 : Office Mean Sitting Diastolic Blood Pressure ≥ 95 mmHg and < 110 mmHg before application of Ambulatory Blood Pressure Measurement device At Visit 3 : 24-hr Mean Ambulatory Diastolic Blood Pressure ≥ 85 mmHg
- •Patient must have an absolute difference of ≤ 10 mmHg in their office Mean Sitting Diastolic Blood Pressure between Visit 2 and
- •Male or female patients are eligible. Female patients must be either post-menopausal for at least one year, surgically sterile or using effective contraceptive methods such as oral contraceptives, barrier method with spermicide or an intrauterine device. Reliable contraception should be maintained throughout the study and for 7 days after study drug discontinuation.
- •Patients who are eligible and able to participate in the study, and who consent to do so after the purpose and nature of the investigation has been clearly explained to them (written informed consent).
排除标准
- •Severe hypertension [Office Mean Sitting Diastolic Blood Pressure ≥ 110 mmHg and/or office mean sitting systolic blood pressure (MSSBP) ≥ 180 mmHg].
- •Current diagnosis of heart failure (NYHA Class II-IV).
- •History of myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention (PCI) during the 12 months prior to Visit
- •Known or suspected contraindications to the study medications, including history of allergy to ACE-Inhibitors or ARBs.
- •Upper arm circumference > 42 cm.
- •Third shift or night workers.
- •Other protocol-defined inclusion/exclusion criteria may apply
结局指标
主要结局
from baseline.
Mean 24-hour ambulatory diastolic blood pressure (MADBP) change from baseline, after a missed dose, aliskiren 300 mg versus irbesartan 300mg.
Mean 24-hour ambulatory diastolic blood pressure (MADBP) change from baseline, after a missed dose, ramipril 10 mg versus irbesartan 300mg.
次要结局
- efficacy on mean 24 hour ambulatory systolic blood pressure (MASBP) change
- from baseline following a missed dose
- efficacy on the MASBP and MADBP change from baseline following the last active dose prior to introducing a missed dose in any treatment group.
- efficacy on daytime and nighttime MASBP and MADBP change from baseline following a missed dose
- efficacy on the daytime and nighttime MASBP and MADBP change from baseline, following the last active dose prior to introducing a missed dose in any treatment group.
- safety and tolerability
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential HypertensionEssential HypertensionNCT01237223Novartis1,342
已完成
4 期
Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes MellitusHypertensionNCT00927394Novartis1,143
已完成
3 期
Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302)HypertensionNCT00092209Organon and Co840
已完成
3 期
Fimasartan in the Senior SubjectsThe Elderly (≥ 70 Years) With Essential HypertensionNCT03246555Boryung Pharmaceutical Co., Ltd241
已完成
3 期
Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate HypertensionHypertensionNCT00262236Novartis693